Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma

Publisher Website
Google Scholar
Abstract
A phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma was conducted. The i.v. dose was 250 mg/m2 per days 1-3 repeated at 3 wk intervals. There were 2 objective regressions (5%) in conjunction with generally transient and tolerable hematologic and gastrointestinal toxicity. L-Alanosine has limited activity against malignant melanoma.